Journal
New England Journal of Medicine
Publication Date
9-22-2022
Volume
387
Issue
12
First Page
1099
Last Page
1110
Document Type
Open Access Publication
DOI
10.1056/NEJMoa2204705
Rights and Permissions
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. Copyright © 2022 Massachusetts Medical Society. Reprinted with permission.
Recommended Citation
Miller, Timothy M; Bucelli, Robert C; and et al., "Trial of antisense oligonucleotide tofersen for SOD1 ALS." New England Journal of Medicine. 387, 12. 1099 - 1110. (2022).
https://digitalcommons.wustl.edu/oa_4/1995
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
